These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 2861351

  • 1. Ifosfamide, mesna, and encephalopathy.
    Lancet; 1985 Jun 15; 1(8442):1398-9. PubMed ID: 2861351
    [No Abstract] [Full Text] [Related]

  • 2. Encephalopathy associated with ifosphamide/mesna therapy.
    Meanwell CA, Blake AE, Latief TN, Blackledge G, Mould JJ, Blake DR, Shaw IC, Honigsberger L, Spooner D, Williams AC.
    Lancet; 1985 Feb 16; 1(8425):406-7. PubMed ID: 2857462
    [No Abstract] [Full Text] [Related]

  • 3. Irreversible encephalopathy with ifosfamide/mesna.
    Salloum E, Flamant F, Ghosn M, Taleb N, Akatchereian C.
    J Clin Oncol; 1987 Aug 16; 5(8):1303-4. PubMed ID: 3114437
    [No Abstract] [Full Text] [Related]

  • 4. Ifosfamide/mesa and encephalopathy.
    Cantwell BM, Harris AL.
    Lancet; 1985 Mar 30; 1(8431):752. PubMed ID: 2858016
    [No Abstract] [Full Text] [Related]

  • 5. Prediction of ifosfamide/mesna associated encephalopathy.
    Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G.
    Eur J Cancer Clin Oncol; 1986 Jul 30; 22(7):815-9. PubMed ID: 3095121
    [Abstract] [Full Text] [Related]

  • 6. Ifosfamide/mesna and hematuria.
    Pratt CB, Goren MP.
    Cancer Treat Rep; 1987 Nov 30; 71(11):1124-5. PubMed ID: 3119210
    [No Abstract] [Full Text] [Related]

  • 7. [Encephalopathy caused by an ifosfamide-mesna combination].
    Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Livartowski A, Palangie T, Scholl S, Pouillart P.
    Presse Med; 1988 Apr 02; 17(12):591-2. PubMed ID: 2967486
    [No Abstract] [Full Text] [Related]

  • 8. Fatal encephalopathy with ifosfamide/mesna.
    Verdeguer A, Castel V, Esquembre C, Ferris J, Fernandez JM, Ruiz JG.
    Pediatr Hematol Oncol; 1989 Apr 02; 6(4):383-5. PubMed ID: 2518327
    [No Abstract] [Full Text] [Related]

  • 9. Ifosfamide/mesna encephalopathy.
    McCallum AK.
    Lancet; 1987 Apr 25; 1(8539):987. PubMed ID: 2882385
    [No Abstract] [Full Text] [Related]

  • 10. Encephalopathy with rapid infusion ifosfamide/mesna.
    Perren TJ, Turner RC, Smith IE.
    Lancet; 1987 Feb 14; 1(8529):390-1. PubMed ID: 2880199
    [No Abstract] [Full Text] [Related]

  • 11. Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
    Ghosn M, Carde P, Leclerq B, Flamant F, Friedman S, Droz JP, Hayat M.
    Bull Cancer; 1988 Feb 14; 75(4):391-2. PubMed ID: 3132998
    [Abstract] [Full Text] [Related]

  • 12. Avoiding ifosfamide/mesna encephalopathy.
    Meanwell CA, Kelly KA, Blackledge G.
    Lancet; 1986 Aug 16; 2(8503):406. PubMed ID: 2874408
    [No Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD, Munshi N, Einhorn LH, Loehrer PJ.
    Cancer Invest; 1990 Aug 16; 8(2):269. PubMed ID: 2119246
    [No Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
    Matthiessen W, Stempinski E, Göbel D, Thalmann U.
    Cancer Treat Rev; 1983 Sep 16; 10 Suppl A():121-3. PubMed ID: 6414688
    [No Abstract] [Full Text] [Related]

  • 15. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
    Steger GG, Dittrich C, Schlappack O, Mader R, Herold C, Brade WP, Keller A, Moser K.
    J Cancer Res Clin Oncol; 1988 Sep 16; 114(6):602-4. PubMed ID: 3144554
    [Abstract] [Full Text] [Related]

  • 16. Severe renal failure following high-dose ifosfamide and mesna.
    Willemse PH, de Jong PE, Elema JD, Mulder NH.
    Cancer Chemother Pharmacol; 1989 Sep 16; 23(5):329-30. PubMed ID: 2495864
    [Abstract] [Full Text] [Related]

  • 17. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
    Hilgard P, Burkert H.
    Eur J Cancer Clin Oncol; 1984 Nov 16; 20(11):1451-2. PubMed ID: 6437825
    [No Abstract] [Full Text] [Related]

  • 18. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
    Sangster G, Kaye SB, Calman KC, Dalton JF.
    Eur J Cancer Clin Oncol; 1984 Mar 16; 20(3):435-6. PubMed ID: 6423391
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
    Fosså SD, Talle K.
    Cancer Treat Rep; 1980 Mar 16; 64(10-11):1103-8. PubMed ID: 6780190
    [Abstract] [Full Text] [Related]

  • 20. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy.
    Husband DJ, Watkin SW.
    Lancet; 1988 May 14; 1(8594):1116. PubMed ID: 2896952
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.